{"data":[{"idconsultant":"1","user_iduser":"1","availabilty":"It all depends...,Hours per week","availabiltyhours":"5 to 15","rate":"120","treatment":"Biologics\/Biosimilars,Oligonucleotides,Small Molecules","smallmolecule":"Small Molecule","smallmoleculedev":"Scale Up,Drug Substance","biologic":"","biologicdev":"Drug Substance","oligo":"DNA","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"Preclinical Specialty Studies","toxicclinicle":"Standard toxicology packages,Genotoxicology","toxicqualification":"","pathology":"","adme":"","pharmacology":"Infectious Disease","devplans":"Clinical Strategy application","experience":"Clinical Pharmacologist,Coordinator,CRA","phases":"Phase 0","areas":"","protocoldev":"","jurisdiction":"","operations":"Document Submission","submissionexperience":"IND or equivalent","regulatorystrat":"505(b)(1","regulatorystratpathway":"","safety":"Immunology","network":"North America,Europe,Israel","networkeu":"Germany,Italy","networkasia":"","bumgmt":"","budev":"","commercestrat":"Launch Planning","iduser":"1","name":"Rudi","email":"rudi.erlemann@gmail.com","company":"Test","website":"","linkedIn":"","city":"","country":"","state":"","phone":"","note":""},{"idconsultant":"15","user_iduser":"10","availabilty":"It all depends...,Short-Term Engagement,Long-","availabiltyhours":"5 ","rate":"350","treatment":"Biologics\/Biosimilars,Gene therapies","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,IV Injection \/ Bolus,IV Infusion","toxicology":"Preclinical Specialty Studies,application Plans,Gap Analysis,Procurement","toxicclinicle":"Safety Assessment,Safety Pharmacology ","toxicqualification":"ERT,DABT","pathology":"","adme":"General DMPK drug discovery","pharmacology":"Oncology & Immuno-Oncology,Ocular Disease","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe,UK","operations":"Document preparation,Document Submission","submissionexperience":"Pre-IND or equivalent,BLA or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"Interim management","budev":"Due Diligence,Pharma & Biotech,(E)Valuations","commercestrat":"","iduser":"10","name":"J\u00f6rg Herbst","email":"jherbst@ncma-consulting.com","company":"NCMA Consulting GmbH","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+41 78 6224688","note":""},{"idconsultant":"17","user_iduser":"12","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Biologics\/Biosimilars,Cell Therapy,Small Molecule,Gene therapies","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"North America","networkeu":"","networkasia":"","bumgmt":"Interim management","budev":"Research and IP Evaluation,Due Diligence,Deal Making & Partnering","commercestrat":"","iduser":"12","name":"Erin Overstreet","email":"erin@sweeneybiomedconsulting.com","company":"Sweeney Biomed Consulting, LLC","website":"","linkedIn":"","city":"","country":"","state":"","phone":"3233632749","note":""},{"idconsultant":"18","user_iduser":"13","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecule,Biologics\/Biosimilars,Oligonucleotides,Cell Therapy,Gene therapies","smallmolecule":"Small Molecules,Sugars,Cytotoxic","smallmoleculedev":"Process application,Scale Up,Drug Substance,Drug Product,Analytical","biologic":"Antibodies,Blood (and blood components),Therapeutic proteins,Allergenics,Vaccines","biologicdev":"Process application,Scale Up,Drug Substance,Drug Product,Analytical","oligo":"mRNA,siRNA,ASO,miRNA,DNA","oligodev":"Process application,Scale Up,Drug Substance,Drug Product,Analytical","celltherapiedev":"Process application,Scale Up,Drug Substance,Drug Product,Analytical","genetherapie":"Plasmids,Viral Vectors,Bacterial Vectors,Transduced\/ genetically-modified cells,Nanoparticles","genetherapiedev":"Process application,Scale Up,Drug Substance,Drug Product,Analytical","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"Cardiovascular \/ Metabolic Diseases,Dermatology,Infectious Disease,Inflammation & Autoimmune,Musculoskeletal Diseases","devplans":"","experience":"","phases":"","areas":"","protocoldev":"Bioavailability,Bioequivalence,Dose-ranging,Drug-drug interactions,Special populations","jurisdiction":"US,Europe","operations":"Document preparation,Document Submission","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent,BLA or equivalent,ANDA or equivalent","regulatorystrat":"Expedited approval pathways,505 (j) ANDA,Orphan drug designation,505(b)(1,505(b)(2) \/ Value Added Medicines,510K,351K,Pediatric plans or equivalent,Product assessment and classification,Special protocol assessments,Postmarketing and surveillance","regulatorystratpathway":"Breakthrough therapy,Fast-track,Priority review,Accelerated Approval","safety":"Analytical Chemistry,Bioanalysis,Immunology,Medical Writing,Pharmacokinetics","network":"North America,Europe","networkeu":"","networkasia":"","bumgmt":"Interim management,Authoring Business Plans","budev":"Research and IP Evaluation,Asset Scouting,Due Diligence,Pharma & Biotech,(E)Valuations","commercestrat":"Corporate Strategy,Fund Raising,Launch Planning,New Product Planning,Opportunity Mapping","iduser":"13","name":"Sol Bobst MBA PhD DABT","email":"sol@toxsciadvisors.com","company":"ToxSci Advisors LLC","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+1 8325812686","note":""},{"idconsultant":"19","user_iduser":"14","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Devices,Small Molecule,Biologics\/Biosimilars,Gene therapies,Food\/dietary supplements","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,Sublingual,IV Injection \/ Bolus,IV Infusion,Inhalation,Intranasal,Intratracheal,Intrathecal,Intercranial,Dermal,Ocular,Intravesical,Intravaginal","toxicology":"Preclinical Specialty Studies","toxicclinicle":"","toxicqualification":"DVM,DABT,ERT","pathology":"15","adme":"PK modelling","pharmacology":"Cardiovascular \/ Metabolic Diseases,Infectious Disease,Dermatology,Inflammation & Autoimmune,Ocular Disease,Oncology & Immuno-Oncology,Respiratory Disease","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"Medical Writing,Pharmacokinetics,Quality Assurance","network":"North America,Europe,Israel,United Kingdom","networkeu":"France,Germany","networkasia":"","bumgmt":"","budev":"Due Diligence,Pharma & Biotech","commercestrat":"Corporate Strategy","iduser":"14","name":"Elizabeth","email":"elizabeth@flanderstoxpath-consulting.com","company":"ElizabethToxPath Consulting Inc.","website":"","linkedIn":"","city":"","country":"","state":"","phone":"16083068","note":""},{"idconsultant":"22","user_iduser":"18","availabilty":"Hours per week","availabiltyhours":"Up to 5","rate":"0","treatment":"Small Molecule,Biologics\/Biosimilars,Cell Therapy,Gene therapies","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"Phase 0,Phase 1,Phase 2,Phase 3","areas":"Oncology,Pulmonary","protocoldev":"Non-inferiority\/superiority studies,Dose-ranging,Bioavailability,Bioequivalence","jurisdiction":"US,Europe","operations":"","submissionexperience":"","regulatorystrat":"Expedited approval pathways,505(b)(1,Orphan drug designation","regulatorystratpathway":"Breakthrough therapy,Fast-track,Priority review,Accelerated Approval","safety":"","network":"North America","networkeu":"","networkasia":"","bumgmt":"Authoring Business Plans","budev":"Due Diligence","commercestrat":"Corporate Strategy,New Product Planning","iduser":"18","name":"Dr. Sameena Sharif","email":"sharifs_99@yahoo.com","company":"4DMT","website":"","linkedIn":"","city":"","country":"","state":"","phone":"19257190884","note":""},{"idconsultant":"24","user_iduser":"20","availabilty":"Short-Term Engagement,Long-Term Engagement,It","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Gene Therapies","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,IV Injection \/ Bolus,IV Infusion,Inhalation","toxicology":"Preclinical Specialty Studies,Application Plans,Gap Analysis,Procurement","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"General DMPK drug discovery,Drug-Drug Interaction,Transporter assays","pharmacology":"Cardiovascular \/ Metabolic Diseases,Inflammation & Autoimmune","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe,UK","operations":"Document preparation","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent","regulatorystrat":"Expedited approval pathways,505(b)(1,505(b)(2) \/ Value Added Medicines","regulatorystratpathway":"Fast-track,Accelerated Approval,Priority review","safety":"Medical Writing,Bioanalysis","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"20","name":"William Heydorn","email":"weheydorn@gmail.com","company":"Independent Consultant","website":"","linkedIn":"","city":"","country":"","state":"","phone":"19736509301","note":""},{"idconsultant":"25","user_iduser":"21","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Ocular","toxicology":"Preclinical Specialty Studies,Application Plans,Gap Analysis,Procurement","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"Document preparation","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"Medical Writing","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"21","name":"Rose Verhoeven","email":"rose@littlecreekresearch.com","company":"Little Creek Research","website":"","linkedIn":"","city":"","country":"","state":"","phone":"19194750505","note":""},{"idconsultant":"26","user_iduser":"22","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Oligonucleotides","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,Sublingual,IV Injection \/ Bolus,IV Infusion,Intratracheal,Dermal,Subcutaneous","toxicology":"Preclinical Specialty Studies","toxicclinicle":"","toxicqualification":"DABT","pathology":"","adme":"General DMPK drug discovery","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"22","name":"David (Dave) Edwards","email":"dbetox@comcast.net","company":"DBETox Consulting","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+116784277804","note":""},{"idconsultant":"27","user_iduser":"23","availabilty":"It all depends...,Short-Term Engagement,Long-","availabiltyhours":"mo","rate":"0","treatment":"Small Molecules,Cell Therapies","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,Sublingual,IV Injection \/ Bolus,Inhalation","toxicology":"Preclinical Specialty Studies,Gap Analysis","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"General DMPK drug discovery,Drug-Drug Interaction,Metabolite identification by LC-MSMS,Transporter assays,PK modelling","pharmacology":"Cardiovascular \/ Metabolic Diseases,Infectious Disease,Inflammation & Autoimmune","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US","operations":"Document preparation","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"Analytical Chemistry,Bioanalysis,Medical Writing,Pharmacokinetics","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"Due Diligence,Research and IP Evaluation,Pharma & Biotech ","commercestrat":"","iduser":"23","name":"Richard E. Ridgewell, PhD","email":"reridgewell@gmail.com","company":"Ridgewell Consulting LLC","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+1 612 868 6175","note":""},{"idconsultant":"28","user_iduser":"24","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Cell Therapies,Gene Therapies,Devices","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"North America,Europe,United Kingdom","networkeu":"","networkasia":"","bumgmt":"Interim management","budev":"","commercestrat":"Corporate Strategy,Launch Planning,New Product Planning,Opportunity Mapping","iduser":"24","name":"Victoria Danilchouk","email":"victoria.danilchouk@pretiumstrategy.com","company":"Pretium Strategy","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+32473837670","note":""},{"idconsultant":"29","user_iduser":"25","availabilty":"Hours per week","availabiltyhours":"5 to 15","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Oligonucleotides","smallmolecule":"","smallmoleculedev":"","biologic":"Antibodies","biologicdev":"Analytical","oligo":"mRNA","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"Drug-Drug Interaction","pharmacology":"","devplans":"","experience":"Clinical Pharmacologist","phases":"Phase 1,Phase 2,Phase 3,Phase 4 - Post Commercialization","areas":"Infectious disease,Neuro,Oncology,Pediatric,GI,Pulmonary,Rare","protocoldev":"Bioavailability,Bioequivalence,Dose-ranging,Drug-drug interactions,Special populations ","jurisdiction":"US,Europe,Australia,UK,Canada,Japan","operations":"Document preparation","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent,ANDA or equivalent,BLA or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"North America,United Kingdom,Asia","networkeu":"","networkasia":"","bumgmt":"Interim management","budev":"Due Diligence","commercestrat":"","iduser":"25","name":"Ashley Milton","email":"ashley.inmass@gmail.com","company":"KHM Pharma Consulting LLC","website":"","linkedIn":"","city":"","country":"","state":"","phone":"617 710 4202","note":""},{"idconsultant":"30","user_iduser":"26","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Oligonucleotides,Biologics\/Biosimilars,Cell Therapies","smallmolecule":"","smallmoleculedev":"","biologic":"Antibodies,Blood (and blood components)","biologicdev":"Process application,Scale Up,Drug Substance","oligo":"mRNA,siRNA,miRNA,DNA","oligodev":"Process application,Scale Up,Drug Substance","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"Cardiovascular \/ Metabolic Diseases,Inflammation & Autoimmune","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"26","name":"Benjamin Dumont","email":"benjamin.dumont294@outlook.com","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"5145695238","note":""},{"idconsultant":"31","user_iduser":"27","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Cell Therapies,Oligonucleotides","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"Infectious disease,Oncology","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"Research and IP Evaluation,Asset Scouting,Due Diligence,Pharma & Biotech ,(E)Valuations","commercestrat":"Corporate Strategy,Opportunity Mapping","iduser":"27","name":"Lior Carmon","email":"lior@bim-consulting.me","company":"Biopharma IM","website":"","linkedIn":"","city":"","country":"","state":"","phone":"0545201166","note":""},{"idconsultant":"32","user_iduser":"28","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Devices,Small Molecules,Biologics\/Biosimilars,Bacterials,Botanicals","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"Medical Writing","network":"North America,Europe","networkeu":"Germany","networkasia":"China","bumgmt":"Authoring Business Plans","budev":"","commercestrat":"Corporate Strategy,Launch Planning","iduser":"28","name":"Linda Miller","email":"miller@smalldogcommunications.ca","company":"Small Dog Communications Inc.","website":"","linkedIn":"","city":"","country":"","state":"","phone":"1 514 892 6355","note":""},{"idconsultant":"33","user_iduser":"29","availabilty":"It all depends...,Hours per week","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Cell Therapies","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,Sublingual,IV Injection \/ Bolus,IV Infusion,Inhalation","toxicology":"Preclinical Specialty Studies,Gap Analysis,Application Plans","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"Expedited approval pathways,Orphan drug designation","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"29","name":"Dr CD Nigel Toseland FRCPath ","email":"nigel.toseland@btinternet.com","company":"Nigel Toseland Consultancy Ltd","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+44 7843776635","note":""},{"idconsultant":"34","user_iduser":"30","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Oligonucleotides,Biologics\/Biosimilars","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Inhalation","toxicology":"Preclinical Specialty Studies","toxicclinicle":"","toxicqualification":"ERT","pathology":"","adme":"","pharmacology":"Respiratory Disease","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"30","name":"detlef","email":"schuler@s-t-c.eu","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+4915755189939","note":""},{"idconsultant":"35","user_iduser":"31","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Gene Therapies","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,Sublingual,IV Injection \/ Bolus,IV Infusion","toxicology":"Preclinical Specialty Studies","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"Cardiovascular \/ Metabolic Diseases,Neurosciences,Rare Disease","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"31","name":"Craig Thomas","email":"craig@thomapharma.com","company":"ThomaPharma","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+13179663347","note":""},{"idconsultant":"36","user_iduser":"32","availabilty":"Long-Term Engagement","availabiltyhours":"","rate":"0","treatment":"Devices,Small Molecules,Biologics\/Biosimilars","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"Clinical Strategy application","experience":"CRA,Data Management,Project Manager","phases":"Phase 0,Phase 1,Phase 2,Phase 3,Phase 4 - Post Commercialization","areas":"Neuro,Oncology","protocoldev":"Bioavailability,Bioequivalence,Dose-ranging,Drug-drug interactions,Safety and efficacy,Crossover designs,Placebo-controlled studies,Quality of life","jurisdiction":"US,Europe,China,Australia,UK,Japan,Brazil","operations":"Document Submission,Document preparation","submissionexperience":"IND or equivalent,NDA or equivalent,BLA or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"Medical Writing,Pharmacovigilance,Pharmacokinetics","network":"North America","networkeu":"","networkasia":"","bumgmt":"Authoring Business Plans","budev":"Research and IP Evaluation,Pharma & Biotech ","commercestrat":"Corporate Strategy,Opportunity Mapping","iduser":"32","name":"Ritu Verma","email":"vermadrrits@gmail.com","company":"Aaransh Inc","website":"","linkedIn":"","city":"","country":"","state":"","phone":"6504681305","note":""},{"idconsultant":"37","user_iduser":"33","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Devices","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"Launch Planning,New Product Planning,Fund Raising","iduser":"33","name":"Farah Virani","email":"fvirani14@gmail.com","company":"Standard BioTools","website":"","linkedIn":"","city":"","country":"","state":"","phone":"4164510359","note":""},{"idconsultant":"38","user_iduser":"34","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Cell Therapies,Biologics\/Biosimilars","smallmolecule":"","smallmoleculedev":"","biologic":"Antibodies,Vaccines,Therapeutic proteins","biologicdev":"Drug Substance,Drug Product,Analytical","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"Indication Selection,Clinical Strategy application,Target Product Profile","experience":"","phases":"Phase 0,Phase 1,Phase 2","areas":"Infectious disease,Oncology,Neuro","protocoldev":"Dose-ranging","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"Research and IP Evaluation,Asset Scouting,Due Diligence,Pharma & Biotech ,(E)Valuations","commercestrat":"Corporate Strategy,Opportunity Mapping,New Product Planning","iduser":"34","name":"Lior Carmon","email":"lior@bim-consulting.me","company":"Biopharma IM","website":"","linkedIn":"","city":"","country":"","state":"","phone":"0545201166","note":""},{"idconsultant":"39","user_iduser":"36","availabilty":"Long-Term Engagement","availabiltyhours":"","rate":"0","treatment":"Small Molecules","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"Europe","networkeu":"Germany","networkasia":"","bumgmt":"Authoring Business Plans,Interim management","budev":"Research and IP Evaluation,Pharma & Biotech ,(E)Valuations,Asset Scouting","commercestrat":"Corporate Strategy,Fund Raising,Opportunity Mapping","iduser":"36","name":"Andreas Bastian ","email":"andreas.a.bastian81@gmail.com","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+49 1603158516","note":""},{"idconsultant":"40","user_iduser":"37","availabilty":"Short-Term Engagement,Hours per week","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Devices","smallmolecule":"","smallmoleculedev":"","biologic":"Antibodies","biologicdev":"Drug Product,Scale Up","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,Sublingual,IV Injection \/ Bolus,IV Infusion,Inhalation,Intranasal,Subcutaneous,Ocular","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"General DMPK drug discovery","pharmacology":"","devplans":"Indication Selection,Target Product Profile,Clinical Strategy application","experience":"","phases":"Phase 1,Phase 0,Phase 2,Phase 3","areas":"GI,Oncology,Pediatric,Pulmonary","protocoldev":"Bioavailability,Dose-ranging,Safety and efficacy","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"Pharmacokinetics","network":"United Kingdom,Israel,North America,Europe","networkeu":"Switzerland,France,Belgium,Germany,Italy","networkasia":"","bumgmt":"Interim management","budev":"Research and IP Evaluation,Due Diligence,Pharma & Biotech ","commercestrat":"Corporate Strategy,New Product Planning","iduser":"37","name":"mark","email":"mark@p2c-pharma.com","company":"P2C Pharma Ltd","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+447813680602","note":""},{"idconsultant":"42","user_iduser":"40","availabilty":"Short-Term Engagement,It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Bacterials,Biologics\/Biosimilars,Gene Therapies","smallmolecule":"","smallmoleculedev":"","biologic":"Antibodies,Vaccines","biologicdev":"Scale Up,Drug Substance,Drug Product","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,China,Europe,Japan","operations":"","submissionexperience":"IND or equivalent,NDA or equivalent,BLA or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"40","name":"Douglas M. Kremer","email":"dmkremer@gmail.com","company":"Private","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+18604602318","note":""},{"idconsultant":"43","user_iduser":"44","availabilty":"Hours per week","availabiltyhours":"","rate":"0","treatment":"Biologics\/Biosimilars,Oligonucleotides,Small Molecules,Gene Therapies","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"Indication Selection,Clinical Strategy application,Target Product Profile","experience":"CRA,Data Management,Clinical Scientist ","phases":"Phase 1,Phase 2,Phase 3,Phase 4 - Post Commercialization","areas":"Oncology,Pediatric,Rare","protocoldev":"Special populations ,Quality of life,Safety and efficacy","jurisdiction":"US,Canada,Europe","operations":"Document preparation","submissionexperience":"Pre-IND or equivalent,IND or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"Medical Writing,Bioanalysis,Immunology,Quality Assurance,Pharmacokinetics,Analytical Chemistry","network":"North America","networkeu":"","networkasia":"","bumgmt":"Interim management,Authoring Business Plans","budev":"Research and IP Evaluation,Pharma & Biotech ","commercestrat":"Corporate Strategy,Opportunity Mapping","iduser":"44","name":"Guy Tremblay","email":"guy.tremblay@gmail.com","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"5147096458","note":""},{"idconsultant":"45","user_iduser":"47","availabilty":"Long-Term Engagement","availabiltyhours":"","rate":"0","treatment":"Biologics\/Biosimilars,Small Molecules,Gene Therapies","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"Phase 1,Phase 2,Phase 3","areas":"Infectious disease,Oncology","protocoldev":"Special populations ,Safety and efficacy,Placebo-controlled studies","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"United Kingdom,Europe,North America,Asia","networkeu":"Belgium,France","networkasia":"China,Japan","bumgmt":"Interim management,Authoring Business Plans","budev":"Pharma & Biotech ","commercestrat":"Corporate Strategy","iduser":"47","name":"John Sheridan","email":"sheridj@skynet.be","company":"Interim Solutions","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+32 486222101","note":""},{"idconsultant":"46","user_iduser":"48","availabilty":"Long-Term Engagement,Hours per week","availabiltyhours":"Up to 5","rate":"0","treatment":"Cell Therapies,Gene Therapies,Oligonucleotides","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"siRNA,miRNA,mRNA,DNA","oligodev":"Process application,Analytical","celltherapiedev":"Process application,Analytical","genetherapie":"Plasmids,Viral Vectors,Transduced\/ genetically-modified cells,Nanoparticles","genetherapiedev":"Process application,Drug Product,Analytical","administrationroute":"IV Infusion","toxicology":"Preclinical Specialty Studies","toxicclinicle":"Immunotoxicology","toxicqualification":"ACVP","pathology":"9","adme":"General DMPK drug discovery,Drug-Drug Interaction","pharmacology":"Neurosciences,Cardiovascular \/ Metabolic Diseases,Oncology & Immuno-Oncology","devplans":"Indication Selection","experience":"Project Manager","phases":"Phase 0,Phase 1,Phase 2","areas":"Neuro,Oncology","protocoldev":"Bioavailability,Drug-drug interactions","jurisdiction":"US,Europe,Australia","operations":"Document preparation","submissionexperience":"IND or equivalent","regulatorystrat":"Expedited approval pathways,510K,Orphan drug designation","regulatorystratpathway":"Fast-track","safety":"Immunology,Pharmacokinetics","network":"North America,Europe,Israel,Asia","networkeu":"Germany,France,Switzerland,Belgium","networkasia":"Japan","bumgmt":"Interim management","budev":"Research and IP Evaluation,Due Diligence,Pharma & Biotech ,Deal Making & Partnering","commercestrat":"Fund Raising,Corporate Strategy,Opportunity Mapping","iduser":"48","name":"Michael Rossbach","email":"rossbach@ikxinta.com","company":"Ikxinta Pte Ltd","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+4915155058981","note":""},{"idconsultant":"47","user_iduser":"49","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules","smallmolecule":"Small Molecules","smallmoleculedev":"Process application,Drug Substance,Analytical,Scale Up","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe,Canada,Australia,Japan","operations":"","submissionexperience":"IND or equivalent,ANDA or equivalent,Pre-IND or equivalent","regulatorystrat":"505(b)(1,505(b)(2) \/ Value Added Medicines","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"49","name":"Stefan Wodzinski ","email":"swodzinski@acanthuspharma.com","company":"Acantus Pharma Services Inc.","website":"","linkedIn":"","city":"","country":"","state":"","phone":"","note":""},{"idconsultant":"48","user_iduser":"50","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules","smallmolecule":"Small Molecules","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"Phase 0,Phase 1","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"Analytical Chemistry","network":"North America,Europe,United Kingdom","networkeu":"","networkasia":"","bumgmt":"","budev":"Research and IP Evaluation,Deal Making & Partnering","commercestrat":"New Product Planning","iduser":"50","name":"Stefan Wodzinski","email":"swodzinski@acanthuspharma.com","company":"Acanthus Pharma Services Inc.","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+16475215616","note":""},{"idconsultant":"49","user_iduser":"51","availabilty":"Long-Term Engagement,Short-Term Engagement,Hours per week","availabiltyhours":"5 to 15","rate":"0","treatment":"Small Molecules,Gene Therapies","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,IV Injection \/ Bolus,Intrathecal,Intercranial,Dermal,Subcutaneous,Ocular","toxicology":"Preclinical Specialty Studies,Gap Analysis","toxicclinicle":"Standard toxicology packages,Juvenile Toxicology,Safety Assessment","toxicqualification":"DABT","pathology":"","adme":"","pharmacology":"Rare Disease,Neurosciences","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe,Australia,UK,Canada,Japan,Brazil","operations":"Document preparation","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"North America","networkeu":"","networkasia":"","bumgmt":"","budev":"Pharma & Biotech ","commercestrat":"","iduser":"51","name":"Jay Stallons","email":"Jay@TiresiasLLC.com","company":"Tiresias Consulting LLC","website":"","linkedIn":"","city":"","country":"","state":"","phone":"13174483042","note":""},{"idconsultant":"50","user_iduser":"52","availabilty":"Short-Term Engagement,Long-Term Engagement,Hours per week","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Bacterials,Botanicals","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"Target Product Profile,Clinical Strategy application,Indication Selection","experience":"Project Manager","phases":"Phase 0,Phase 1,Phase 2,Phase 3,Phase 4 - Post Commercialization","areas":"GI,Infectious disease,Neuro,Pediatric,Pulmonary,Rare","protocoldev":"Bioequivalence,Dose-ranging,Drug-drug interactions,Special populations ,Crossover designs,Safety and efficacy,Non-inferiority\/superiority studies,Quality of life","jurisdiction":"US,Europe,China,Australia,UK,new zealand","operations":"","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent","regulatorystrat":"Expedited approval pathways,Orphan drug designation,505(b)(1,505(b)(2) \/ Value Added Medicines,Pediatric plans or equivalent,Product assessment and classification,Special protocol assessments","regulatorystratpathway":"Breakthrough therapy,Fast-track,Priority review,Accelerated Approval","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"52","name":"Aurora Sosa","email":"aurora.sosa@sosaregulatoryconsultingllc.com","company":"Private","website":"","linkedIn":"","city":"","country":"","state":"","phone":"13609140702","note":""},{"idconsultant":"52","user_iduser":"54","availabilty":"Long-Term Engagement","availabiltyhours":"","rate":"0","treatment":"Biologics\/Biosimilars","smallmolecule":"","smallmoleculedev":"","biologic":"Blood (and blood components),Therapeutic proteins","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Sublingual,Oral","toxicology":"","toxicclinicle":"","toxicqualification":"DABT","pathology":"","adme":"","pharmacology":"","devplans":"Clinical Strategy application","experience":"Clinical Scientist ,Clinical Pharmacologist","phases":"Phase 1","areas":"","protocoldev":"Bioavailability","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"54","name":"karlos","email":"rudi.erlemann@hotmail.com","company":"tyeyt","website":"","linkedIn":"","city":"","country":"","state":"","phone":"123456789","note":""},{"idconsultant":"53","user_iduser":"55","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"Preclinical Specialty Studies,Application Plans,Gap Analysis,Procurement","toxicclinicle":"Standard toxicology packages,Inhalation Toxicology,Safety Assessment,Safety Pharmacology ","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"Statistics","network":"North America","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"55","name":"Mark Osier","email":"mark@willowtoxicology.com","company":"Willow Toxicology Consulting, Inc.","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+14254460484","note":""},{"idconsultant":"54","user_iduser":"56","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Oligonucleotides,Small Molecules","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,IV Injection \/ Bolus,Subcutaneous,Ocular","toxicology":"Preclinical Specialty Studies","toxicclinicle":"Standard toxicology packages,Genotoxicology,Juvenile Toxicology,Safety Assessment,Reprotoxicology \/ DART,Safety Pharmacology ","toxicqualification":"DABT","pathology":"20","adme":"","pharmacology":"Inflammation & Autoimmune,Oncology & Immuno-Oncology,Rare Disease","devplans":"","experience":"","phases":"","areas":"Oncology","protocoldev":"","jurisdiction":"US,Europe,UK,Canada","operations":"Document preparation,Document Submission","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent","regulatorystrat":"Expedited approval pathways,Orphan drug designation","regulatorystratpathway":"Fast-track","safety":"Medical Writing","network":"North America","networkeu":"","networkasia":"","bumgmt":"Interim management","budev":"Due Diligence","commercestrat":"Corporate Strategy","iduser":"56","name":"Anthony Trombino","email":"anthony_trombino@hotmail.com","company":"Cambridgeside Associates","website":"","linkedIn":"","city":"","country":"","state":"","phone":"6175840727","note":""},{"idconsultant":"55","user_iduser":"57","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Botanicals","smallmolecule":"Small Molecules,Cytotoxic","smallmoleculedev":"Analytical,Process application,Drug Substance,Drug Product","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"57","name":"Bruce Girton","email":"bcgirton@gmail.com","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+1258308464","note":""},{"idconsultant":"56","user_iduser":"58","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Biologics\/Biosimilars,Small Molecules","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"CRA,Coordinator ,Project Manager","phases":"Phase 4 - Post Commercialization,Phase 1,Phase 2,Phase 3","areas":"Rare,Neuro,Oncology","protocoldev":"Safety and efficacy","jurisdiction":"US,Europe,UK","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"58","name":"Stefan Br\u00c3\u00bcning","email":"mail@stefanbruening.de","company":"Bruening Consulting","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+4915153133259","note":""},{"idconsultant":"57","user_iduser":"59","availabilty":"Long-Term Engagement","availabiltyhours":"","rate":"0","treatment":"Biologics\/Biosimilars,Small Molecules,Cell Therapies,Gene Therapies","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"IV Injection \/ Bolus,Oral,Dermal,IV Infusion,Sublingual,Intrathecal","toxicology":"Preclinical Specialty Studies","toxicclinicle":"Standard toxicology packages,Biocompatability,Genotoxicology,Immunotoxicology,Reprotoxicology \/ DART","toxicqualification":"","pathology":"","adme":"General DMPK drug discovery,Drug-Drug Interaction,Metabolite identification by LC-MSMS,PK modelling","pharmacology":"Oncology & Immuno-Oncology,Dermatology,Infectious Disease,Inflammation & Autoimmune,Rare Disease,Respiratory Disease","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"59","name":"Sudhir Shah","email":"sudhirshah06@yahoo.com","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+12404189202","note":""},{"idconsultant":"58","user_iduser":"60","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Inhalation,Oral,IV Injection \/ Bolus,IV Infusion","toxicology":"Preclinical Specialty Studies,Application Plans,Gap Analysis,Procurement","toxicclinicle":"Standard toxicology packages,Genotoxicology,Inhalation Toxicology,Juvenile Toxicology,Reprotoxicology \/ DART,Safety Assessment,Safety Pharmacology ","toxicqualification":"DABT","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"60","name":"Susan Tantawi","email":"susan@akcella.com","company":"Akcella","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+15148368116","note":""},{"idconsultant":"59","user_iduser":"61","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Biologics\/Biosimilars,Oligonucleotides","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,Sublingual,IV Infusion,Inhalation,Intratracheal,Dermal,Intercranial,Subcutaneous,Ocular,Intravaginal","toxicology":"Preclinical Specialty Studies","toxicclinicle":"Immunotoxicology,Reprotoxicology \/ DART,Safety Assessment,Safety Pharmacology ","toxicqualification":"","pathology":"","adme":"","pharmacology":"Infectious Disease,Inflammation & Autoimmune,Oncology & Immuno-Oncology,Respiratory Disease,Musculoskeletal Diseases","devplans":"Clinical Strategy application,Target Product Profile,Indication Selection","experience":"Clinical Scientist ","phases":"Phase 0,Phase 1,Phase 2,Phase 3,Phase 4 - Post Commercialization","areas":"Infectious disease,Oncology,Pediatric,Pulmonary","protocoldev":"","jurisdiction":"US,Europe,Australia,UK,Japan","operations":"","submissionexperience":"Pre-IND or equivalent,IND or equivalent,BLA or equivalent","regulatorystrat":"505(b)(1,Expedited approval pathways,Special protocol assessments,Pediatric plans or equivalent,Postmarketing and surveillance","regulatorystratpathway":"Fast-track,Priority review,Accelerated Approval,Breakthrough therapy","safety":"Immunology,Bioanalysis","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"Due Diligence,Research and IP Evaluation,Pharma & Biotech ","commercestrat":"Opportunity Mapping,New Product Planning","iduser":"61","name":"Sachin Mani","email":"sachin.mani.2018@gmail.com","company":"Private","website":"","linkedIn":"","city":"","country":"","state":"","phone":"13014619726","note":""},{"idconsultant":"60","user_iduser":"62","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Devices,Botanicals","smallmolecule":"Small Molecules","smallmoleculedev":"Drug Substance,Drug Product,Analytical","biologic":"","biologicdev":"Drug Substance,Drug Product,Analytical","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"General DMPK drug discovery,Drug-Drug Interaction,Metabolite identification by LC-MSMS,Transporter assays","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"North America,Australia","networkeu":"","networkasia":"","bumgmt":"Interim management","budev":"Research and IP Evaluation,Due Diligence,Pharma & Biotech ","commercestrat":"New Product Planning,Corporate Strategy","iduser":"62","name":"Katrina Rogers","email":"katrina@krogersconsulting.com","company":"Katrina Rogers Consulting","website":"","linkedIn":"","city":"","country":"","state":"","phone":"15098183338","note":""},{"idconsultant":"61","user_iduser":"63","availabilty":"It all depends...","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"Canada,US","operations":"Document preparation","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent,BLA or equivalent","regulatorystrat":"505(b)(1,505(b)(2) \/ Value Added Medicines,Expedited approval pathways,Pediatric plans or equivalent,Orphan drug designation,Special protocol assessments","regulatorystratpathway":"Breakthrough therapy,Fast-track,Priority review,Accelerated Approval","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"63","name":"Jason McEwan","email":"jason.j.mcewan@gmail.com","company":"Private","website":"","linkedIn":"","city":"","country":"","state":"","phone":"16133164132","note":""},{"idconsultant":"62","user_iduser":"64","availabilty":"Hours per week","availabiltyhours":"5 to 15","rate":"120","treatment":"Small Molecules,Oligonucleotides","smallmolecule":"Small Molecule","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"ASO","oligodev":"Drug Substance","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"North America,Europe","networkeu":"France,Italy","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"64","name":"Christoph Kramer","email":"christophkramer1@gmx.de","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"","note":""},{"idconsultant":"68","user_iduser":"68","availabilty":"Short-Term Engagement,Long-Term Engagement,Hours per week","availabiltyhours":"more than 15,5 to 15,Up to 5","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Oligonucleotides","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"IV Injection \/ Bolus,IV Infusion","toxicology":"Preclinical Specialty Studies,Application Plans,Gap Analysis","toxicclinicle":"Standard toxicology packages","toxicqualification":"","pathology":"","adme":"General DMPK drug discovery,PK modelling","pharmacology":"Cardiovascular \/ Metabolic Diseases,Infectious Disease","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US","operations":"Document preparation","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"Bioanalysis,Pharmacokinetics","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"68","name":"Dario Lehoux","email":"Dario.lehoux@outlook.com","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"5142471008","note":""},{"idconsultant":"69","user_iduser":"69","availabilty":"Hours per week","availabiltyhours":"more than 15","rate":"240","treatment":"Biologics\/Biosimilars","smallmolecule":"","smallmoleculedev":"","biologic":"Antibodies","biologicdev":"Drug Product","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"69","name":"christoph","email":"christophkramer@gmx.net","company":"","website":"","linkedIn":"Test","city":"","country":"","state":"","phone":"0124234234","note":""},{"idconsultant":"72","user_iduser":"74","availabilty":"Hours per week","availabiltyhours":"5 to 15","rate":"450","treatment":"Small Molecules,Cell Therapies,Gene Therapies,Oligonucleotides","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,IV Infusion,IV Injection \/ Bolus","toxicology":"Preclinical Specialty Studies","toxicclinicle":"Safety Assessment,Safety Pharmacology ","toxicqualification":"","pathology":"","adme":"","pharmacology":"Cardiovascular \/ Metabolic Diseases,Inflammation & Autoimmune,Neurosciences","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe,UK,Japan","operations":"Document preparation","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent,ANDA or equivalent,BLA or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"North America","networkeu":"","networkasia":"","bumgmt":"","budev":"Deal Making & Partnering","commercestrat":"Opportunity Mapping,New Product Planning","iduser":"74","name":"Najah Abi Georges","email":"najah.ag@therapitek.com","company":"TherapiTek","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+18583668374","note":""},{"idconsultant":"73","user_iduser":"75","availabilty":"Long-Term Engagement","availabiltyhours":"","rate":"","treatment":"Small Molecules,Biologics\/Biosimilars,Food\/dietary supplements,Cell Therapies,Botanicals,Oligonucleotides","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,IV Injection \/ Bolus,IV Infusion,Inhalation,Intratracheal,Intranasal,Subcutaneous,Ocular,Dermal","toxicology":"Preclinical Specialty Studies,Application Plans,Gap Analysis,Procurement","toxicclinicle":"Standard toxicology packages,Genotoxicology,Immunotoxicology,Inhalation Toxicology,Juvenile Toxicology,Safety Assessment,Safety Pharmacology ","toxicqualification":"","pathology":"","adme":"General DMPK drug discovery","pharmacology":"Cardiovascular \/ Metabolic Diseases,Inflammation & Autoimmune,Infectious Disease,Respiratory Disease,Neurosciences,Oncology & Immuno-Oncology","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Australia,Europe,Canada,China","operations":"Document preparation","submissionexperience":"IND or equivalent,Pre-IND or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"Immunology,Medical Writing,Pharmacokinetics,Quality Assurance,Statistics","network":"North America","networkeu":"","networkasia":"","bumgmt":"Interim management","budev":"Pharma & Biotech ","commercestrat":"","iduser":"75","name":"Jigneshkumar Vaghasiya","email":"jigneshvaghasiya12@gmail.com","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"12043336571","note":""},{"idconsultant":"74","user_iduser":"76","availabilty":"It all depends...","availabiltyhours":"","rate":"230","treatment":"Small Molecules,Biologics\/Biosimilars,Devices","smallmolecule":"Small Molecules","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"Europe","operations":"Document preparation,Document Submission","submissionexperience":"IND or equivalent,NDA or equivalent,BLA or equivalent","regulatorystrat":"505(b)(1,Pediatric plans or equivalent,Product assessment and classification,Postmarketing and surveillance","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"76","name":"Michaela Katharina Nahler","email":"michaela.nahler@gmail.com","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+41 76 346 5766","note":""},{"idconsultant":"75","user_iduser":"77","availabilty":"Long-Term Engagement,Hours per week,It all depends...","availabiltyhours":"","rate":"275","treatment":"Small Molecules,Biologics\/Biosimilars,Oligonucleotides,Cell Therapies,Gene Therapies,Devices","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,IV Injection \/ Bolus,Inhalation,IV Infusion,Intratracheal,Dermal,Intercranial,Ocular","toxicology":"Preclinical Specialty Studies","toxicclinicle":"Standard toxicology packages,Genotoxicology,Reprotoxicology \/ DART,Juvenile Toxicology","toxicqualification":"","pathology":"","adme":"General DMPK drug discovery,Drug-Drug Interaction","pharmacology":"Dermatology,Cardiovascular \/ Metabolic Diseases,Inflammation & Autoimmune,Ocular Disease,Neurosciences","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe,China,Canada,Brazil,Japan","operations":"Document Submission","submissionexperience":"Pre-IND or equivalent,IND or equivalent,ANDA or equivalent,BLA or equivalent","regulatorystrat":"Expedited approval pathways,Orphan drug designation,505(b)(1,505(b)(2) \/ Value Added Medicines","regulatorystratpathway":"Breakthrough therapy,Fast-track,Priority review,Accelerated Approval","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"77","name":"Farhad Amiri","email":"Farhad_amiri@yahoo.ca","company":"Private","website":"","linkedIn":"","city":"","country":"","state":"","phone":"15142295840","note":""},{"idconsultant":"76","user_iduser":"78","availabilty":"It all depends...","availabiltyhours":"","rate":"250","treatment":"Biologics\/Biosimilars","smallmolecule":"","smallmoleculedev":"","biologic":"Antibodies,Therapeutic proteins","biologicdev":"Process application,Scale Up,Drug Substance,Drug Product,Analytical","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe,China,Australia,Canada,UK","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"78","name":"Katrin Frese","email":"katrin.frese@frese-bc.com","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"4915158561589","note":""},{"idconsultant":"77","user_iduser":"79","availabilty":"It all depends...","availabiltyhours":"","rate":"250","treatment":"Small Molecules","smallmolecule":"Small Molecules,Cytotoxic","smallmoleculedev":"Drug Product,Scale Up","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe","operations":"Document preparation","submissionexperience":"IND or equivalent,NDA or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"79","name":"Rahela Gasparac","email":"rahela@helipharm.com","company":"Helipharm","website":"","linkedIn":"","city":"","country":"","state":"","phone":"857 234 6946","note":""},{"idconsultant":"78","user_iduser":"80","availabilty":"It all depends...,Short-Term Engagement,Long-Term Engagement,Hours per week","availabiltyhours":"more than 15","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Oligonucleotides,Cell Therapies,Gene Therapies","smallmolecule":"Small Molecules","smallmoleculedev":"Drug Substance,Drug Product","biologic":"Antibodies,Vaccines","biologicdev":"Process application,Drug Substance,Drug Product","oligo":"siRNA,miRNA,ASO,mRNA","oligodev":"Drug Substance,Drug Product","celltherapiedev":"Drug Substance,Drug Product","genetherapie":"Viral Vectors","genetherapiedev":"Drug Substance,Drug Product","administrationroute":"Oral,IV Injection \/ Bolus,IV Infusion,Intratracheal,Intranasal,Intercranial,Dermal,Subcutaneous,Ocular,Intravaginal","toxicology":"Preclinical Specialty Studies,Application Plans,Gap Analysis,Procurement","toxicclinicle":"Standard toxicology packages,Biocompatability,Genotoxicology,Immunotoxicology,Juvenile Toxicology,Reprotoxicology \/ DART,Safety Assessment,Safety Pharmacology ","toxicqualification":"DABT","pathology":"","adme":"General DMPK drug discovery,Drug-Drug Interaction","pharmacology":"Cardiovascular \/ Metabolic Diseases,Dermatology,Infectious Disease,Inflammation & Autoimmune,Musculoskeletal Diseases,Neurosciences,Rare Disease,Oncology & Immuno-Oncology","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe,China,Australia,UK","operations":"Document preparation,Document Submission","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent,BLA or equivalent,ANDA or equivalent","regulatorystrat":"Expedited approval pathways,505(b)(1,505(b)(2) \/ Value Added Medicines,Orphan drug designation,510K,Pediatric plans or equivalent,Special protocol assessments","regulatorystratpathway":"Breakthrough therapy,Fast-track,Priority review,Accelerated Approval","safety":"Medical Writing","network":"North America","networkeu":"","networkasia":"","bumgmt":"","budev":"Due Diligence,Pharma & Biotech ","commercestrat":"","iduser":"80","name":"Cindy Roegge","email":"croegge@dunnregulatory.com","company":"Dunn Regulatory Associates, LLC","website":"","linkedIn":"","city":"","country":"","state":"","phone":"6122830348","note":""},{"idconsultant":"79","user_iduser":"81","availabilty":"Long-Term Engagement","availabiltyhours":"","rate":"","treatment":"Small Molecules","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"IND or equivalent","regulatorystrat":"Expedited approval pathways","regulatorystratpathway":"","safety":"Medical Writing","network":"North America","networkeu":"","networkasia":"","bumgmt":"","budev":"Pharma & Biotech ","commercestrat":"New Product Planning","iduser":"81","name":"Andrea Talerico","email":"andrea.talerico@intertek.com","company":"Intertek","website":"","linkedIn":"","city":"","country":"","state":"","phone":"","note":""},{"idconsultant":"80","user_iduser":"82","availabilty":"Hours per week","availabiltyhours":"","rate":"","treatment":"Biologics\/Biosimilars,Small Molecules","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,IV Infusion","toxicology":"Preclinical Specialty Studies","toxicclinicle":"Standard toxicology packages,Immunotoxicology","toxicqualification":"DABT,ERT","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"82","name":"Om Makwana","email":"otmakwan@gmail.com","company":"NA","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+19194554153","note":""},{"idconsultant":"81","user_iduser":"83","availabilty":"It all depends...","availabiltyhours":"","rate":"150","treatment":"Small Molecules,Biologics\/Biosimilars","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"Clinical Strategy application,Target Product Profile","experience":"Project Manager,Medical Director,CRA","phases":"Phase 2,Phase 3,Phase 1","areas":"Infectious disease,GI,Neuro,Oncology,Rare","protocoldev":"Placebo-controlled studies,Safety and efficacy,Non-inferiority\/superiority studies,Quality of life","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"83","name":"Dianne Stephens ","email":"stephens.dianne.l@gmail.com","company":"Dianne Stephens Consulting","website":"","linkedIn":"","city":"","country":"","state":"","phone":"5148942567","note":""},{"idconsultant":"82","user_iduser":"84","availabilty":"It all depends...","availabiltyhours":"","rate":"300","treatment":"Small Molecules,Biologics\/Biosimilars","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,IV Injection \/ Bolus,IV Infusion,Inhalation,Subcutaneous","toxicology":"Preclinical Specialty Studies,Procurement,Gap Analysis,Application Plans","toxicclinicle":"Standard toxicology packages,Inhalation Toxicology,Safety Pharmacology ,Safety Assessment,Immunotoxicology","toxicqualification":"DABT,ERT","pathology":"","adme":"","pharmacology":"Oncology & Immuno-Oncology,Cardiovascular \/ Metabolic Diseases,Inflammation & Autoimmune,Neurosciences","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"84","name":"Om Makwana ","email":"otmakwan@gmail.com","company":"Private","website":"","linkedIn":"","city":"","country":"","state":"","phone":"9194554153","note":""},{"idconsultant":"83","user_iduser":"85","availabilty":"It all depends...","availabiltyhours":"","rate":"240","treatment":"Small Molecules,Biologics\/Biosimilars,Cell Therapies,Gene Therapies,Bacterials,Devices","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"Clinical Strategy application","experience":"Project Manager,CRA","phases":"Phase 1,Phase 2,Phase 3","areas":"Infectious disease,Oncology,Pulmonary,Rare","protocoldev":"Safety and efficacy,Crossover designs,Quality of life,Bioavailability,Bioequivalence,Dose-ranging,Drug-drug interactions","jurisdiction":"Europe,US,UK,Australia,Canada,Japan","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"85","name":"Cornelia Baumgrtner","email":"cornelia@cetacea.ch","company":"Cetacea Clinical GmbH  ","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+41 789130638","note":""},{"idconsultant":"84","user_iduser":"86","availabilty":"It all depends...","availabiltyhours":"","rate":"130","treatment":"Biologics\/Biosimilars,Gene Therapies","smallmolecule":"","smallmoleculedev":"","biologic":"Therapeutic proteins,Antibodies,Vaccines,Blood (and blood components)","biologicdev":"Analytical,Process application,Scale Up,Drug Substance,Drug Product","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"Viral Vectors","genetherapiedev":"Scale Up,Drug Substance,Analytical","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Canada","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"86","name":"Tom Reidy","email":"tjreidy@yahoo.com","company":"Freelance Consultant","website":"","linkedIn":"","city":"","country":"","state":"","phone":"5088470245","note":""},{"idconsultant":"85","user_iduser":"87","availabilty":"It all depends...","availabiltyhours":"","rate":"300","treatment":"Food\/dietary supplements,Small Molecules,Biologics\/Biosimilars,Oligonucleotides,Gene Therapies","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,IV Injection \/ Bolus,IV Infusion,Inhalation,Subcutaneous,Dermal,Intravaginal","toxicology":"Gap Analysis,Preclinical Specialty Studies","toxicclinicle":"Standard toxicology packages,Biocompatability,Inhalation Toxicology,Reprotoxicology \/ DART,Safety Pharmacology ,Safety Assessment","toxicqualification":"ERT","pathology":"","adme":"PK modelling","pharmacology":"Cardiovascular \/ Metabolic Diseases,Respiratory Disease","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"Europe,US,UK,Japan,China","operations":"Document preparation,Document Submission","submissionexperience":"Pre-IND or equivalent,IND or equivalent,BLA or equivalent","regulatorystrat":"Product assessment and classification,505(b)(1,505(b)(2) \/ Value Added Medicines","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"87","name":"Claudius Gro\u00c3\u009fmann","email":"c.grossmann@wtconsulting.ch","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+41 61 923 30 06","note":""},{"idconsultant":"86","user_iduser":"88","availabilty":"It all depends...,Short-Term Engagement,Long-Term Engagement","availabiltyhours":"","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Bacterials,Devices","smallmolecule":"Small Molecules","smallmoleculedev":"Drug Substance,Analytical","biologic":"Antibodies","biologicdev":"Drug Substance","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,IV Injection \/ Bolus,IV Infusion,Dermal,Subcutaneous","toxicology":"Preclinical Specialty Studies,Application Plans,Gap Analysis,Procurement","toxicclinicle":"Standard toxicology packages,Biocompatability,Genotoxicology,Immunotoxicology,Reprotoxicology \/ DART,Safety Assessment,Safety Pharmacology ","toxicqualification":"DABT","pathology":"","adme":"Drug-Drug Interaction,General DMPK drug discovery","pharmacology":"Cardiovascular \/ Metabolic Diseases,Dermatology,Inflammation & Autoimmune,Musculoskeletal Diseases,Neurosciences,Rare Disease","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe,Japan","operations":"Document preparation","submissionexperience":"Pre-IND or equivalent,IND or equivalent,NDA or equivalent,BLA or equivalent","regulatorystrat":"505(b)(1,505(b)(2) \/ Value Added Medicines","regulatorystratpathway":"","safety":"Bioanalysis,Pharmacokinetics,Medical Writing","network":"North America","networkeu":"","networkasia":"","bumgmt":"Interim management","budev":"","commercestrat":"","iduser":"88","name":"Jeff Handler","email":"jeff@jahassociatesllc.com","company":"JAH Associates LLC","website":"","linkedIn":"","city":"","country":"","state":"","phone":"0016102200016","note":""},{"idconsultant":"87","user_iduser":"89","availabilty":"It all depends...","availabiltyhours":"","rate":"275","treatment":"Small Molecules,Biologics\/Biosimilars,Oligonucleotides,Gene Therapies,Cell Therapies,Food\/dietary supplements","smallmolecule":"Small Molecules,Sugars","smallmoleculedev":"Analytical,Drug Product,Drug Substance,Scale Up,Process application","biologic":"Antibodies,Therapeutic proteins,Vaccines","biologicdev":"Process application,Scale Up,Drug Substance,Drug Product,Analytical","oligo":"siRNA,ASO,DNA","oligodev":"Process application,Scale Up,Drug Substance,Drug Product,Analytical","celltherapiedev":"","genetherapie":"Nanoparticles,Plasmids","genetherapiedev":"Process application,Scale Up,Drug Substance,Drug Product,Analytical","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US","operations":"","submissionexperience":"Pre-IND or equivalent,IND or equivalent,BLA or equivalent,NDA or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"89","name":"Evan Wal","email":"evan.walters@innovativeanalytical.com","company":"Innovative Analytical Solutions LLC (IAS)","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+15183318738","note":""},{"idconsultant":"88","user_iduser":"91","availabilty":"It all depends...,Hours per week","availabiltyhours":"more than 15","rate":"0","treatment":"Small Molecules,Biologics\/Biosimilars,Oligonucleotides,Cell Therapies,Gene Therapies,Bacterials,Devices,Food\/dietary supplements","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"Phase 0,Phase 1,Phase 2,Phase 3,Phase 4 - Post Commercialization","areas":"GI,Infectious disease,Neuro,Oncology,Pediatric,Pulmonary,Rare","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"Medical Writing","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"91","name":"Konstantinos Prattas","email":"kprattas@gmail.com","company":"Freelance","website":"","linkedIn":"","city":"","country":"","state":"","phone":"4377793327","note":""},{"idconsultant":"89","user_iduser":"92","availabilty":"It all depends...","availabiltyhours":"","rate":"400","treatment":"Small Molecules,Biologics\/Biosimilars,Bacterials,Devices","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"Oral,IV Injection \/ Bolus,IV Infusion,Dermal,Subcutaneous","toxicology":"Preclinical Specialty Studies,Gap Analysis,Procurement","toxicclinicle":"Standard toxicology packages,Biocompatability,Genotoxicology,Immunotoxicology,Reprotoxicology \/ DART,Safety Assessment,Safety Pharmacology ","toxicqualification":"DABT","pathology":"","adme":"General DMPK drug discovery,Drug-Drug Interaction","pharmacology":"Dermatology,Inflammation & Autoimmune,Cardiovascular \/ Metabolic Diseases,Infectious Disease,Musculoskeletal Diseases,Oncology & Immuno-Oncology,Rare Disease","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe,Japan","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"92","name":"Jeff Handler","email":"jeff@jahassociatesllc.com","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+16102200016","note":""},{"idconsultant":"90","user_iduser":"93","availabilty":"","availabiltyhours":"","rate":"250","treatment":"Small Molecules,Oligonucleotides","smallmolecule":"Small Molecules,Cytotoxic","smallmoleculedev":"Process application,Scale Up,Drug Substance,Drug Product,Analytical","biologic":"","biologicdev":"","oligo":"ASO","oligodev":"Process application,Scale Up,Analytical,Drug Substance","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"US,Europe","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"93","name":"John Wetzel","email":"wetzelchemistryconsulting@gmail.com","company":"Wetzel Chemistry Consulting, LLC","website":"","linkedIn":"","city":"","country":"","state":"","phone":"+12016930031","note":""},{"idconsultant":"91","user_iduser":"94","availabilty":"","availabiltyhours":"","rate":"","treatment":"Biologics\/Biosimilars","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"","devplans":"","experience":"","phases":"","areas":"","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"","networkeu":"","networkasia":"","bumgmt":"","budev":"","commercestrat":"","iduser":"94","name":"dddddd","email":"d@gmail.com","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"","note":""},{"idconsultant":"92","user_iduser":"95","availabilty":"It all depends...","availabiltyhours":"","rate":"","treatment":"Small Molecules,Biologics\/Biosimilars","smallmolecule":"","smallmoleculedev":"","biologic":"","biologicdev":"","oligo":"","oligodev":"","celltherapiedev":"","genetherapie":"","genetherapiedev":"","administrationroute":"","toxicology":"","toxicclinicle":"","toxicqualification":"","pathology":"","adme":"","pharmacology":"Oncology & Immuno-Oncology","devplans":"Indication Selection,Target Product Profile","experience":"","phases":"Phase 0,Phase 1","areas":"Oncology","protocoldev":"","jurisdiction":"","operations":"","submissionexperience":"Pre-IND or equivalent,IND or equivalent","regulatorystrat":"","regulatorystratpathway":"","safety":"","network":"Europe,North America","networkeu":"","networkasia":"","bumgmt":"Interim management,Authoring Business Plans","budev":"Research and IP Evaluation,Asset Scouting,Due Diligence,Pharma & Biotech ","commercestrat":"Corporate Strategy","iduser":"95","name":"Kati Rasanen","email":"kati@katitkotona.com","company":"","website":"","linkedIn":"","city":"","country":"","state":"","phone":"","note":""}],"response": "success" }